个性化塔克罗利斯治疗:CYP3A5多态和肠道新陈代谢的洞察
Mizuki Mishima1, Tomohisa Yabe1, Takaya Kondo1
1Department of Nephrology Kanazawa Medical University Kahoku Japan.
Clinical case reports
|September 9, 2024
概括
在CYP3A5酶的遗传变异可以导致塔克罗利斯剂量折射性. 这一案例突显了CYP3A5遗传多态化对药物代谢和治疗有效性的影响.
科学领域:
- 药物基因组学 药物基因组学
- 药物新陈代谢 药物新陈代谢
- 临床生物化学 临床生物化学
背景情况:
- 细胞染色体P450 3A4 (CYP3A4) 和细胞染色体P450 3A5 (CYP3A5) 是药物代谢中的关键酶.
- 这些酶对于代谢像塔克罗利斯这样的药物至关重要,影响治疗效率.
- CYP3A5主要表达在肝脏,肠道粘膜和脏中.
研究的目的:
- 报告一个临床案例的tacrolimus剂量折射性.
- 调查CYP3A5中的遗传多态性作为治疗不响应的原因.
主要方法:
- 病例报告详细介绍了塔克罗利木斯治疗.
- 基因分析以确定CYP3A5多态性.
- 评估塔克罗利斯代谢和剂量要求.
主要成果:
- 患者对标准的塔克罗利斯剂量表现出折射性.
- 基因分析揭示了CYP3A5基因中的特定多态性.
- 这种多态性被确定为塔克罗利斯代谢受损的可能原因.
结论:
- CYP3A5遗传多态性可能导致塔克罗利斯剂量折射性.
- 对CYP3A5的遗传测试可能对优化塔克罗利斯治疗很重要.
- 了解药物遗传学对于个性化医疗方法至关重要.
更多相关视频
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Hepatic Drug Clearance: Role of Transporters
44
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
44
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
179
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
179
Nonlinear Pharmacokinetics: Role of Transporters
41
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
41
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
103
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
103


